Mindfulness-Based Interventions in Recurrent Ovarian Cancer: A Mixed-Methods Feasibility Study
Emily Arden-Close1, Felicity Mitchell2, Gail Davies3
1Bournemouth University, Poole, Dorset, UK.
Integrative Cancer Therapies
|March 17, 2020
Summary
Mindfulness interventions are feasible for women with recurrent ovarian cancer, showing potential to reduce psychological distress. Further research is needed to confirm effectiveness in managing cancer recurrence challenges.
Area of Science:
- Oncology
- Psychology
- Mindfulness Studies
Background:
- Cancer recurrence is a significant source of psychological distress.
- Mindfulness-based interventions show promise in managing stress and improving coping mechanisms.
- There is a need to evaluate interventions for psychosocial distress in recurrent ovarian cancer.
Purpose of the Study:
- To determine the feasibility and acceptability of a mindfulness-based intervention (MBI) for women with recurrent ovarian cancer.
- To assess the potential impact of an MBI on psychosocial distress in this population.
- To evaluate the delivery of an MBI within a UK hospital setting.
Main Methods:
- A single-arm, mixed-methods study involving 28 participants with recurrent ovarian cancer.
- Participants engaged in a six-week group mindfulness program, with sessions lasting 1.5 hours weekly.
- Feasibility and acceptability were assessed, alongside preliminary impact on psychological distress.
Main Results:
- The mindfulness-based intervention was found to be acceptable and feasible for women with recurrent ovarian cancer.
- The intervention could be delivered within a standard UK cancer care pathway.
- Preliminary results indicated a positive impact on symptoms of depression and anxiety.
Conclusions:
- Mindfulness-based interventions are a feasible and acceptable approach for managing psychosocial distress in recurrent ovarian cancer.
- The intervention shows potential for improving mental well-being in this patient group.
- Further investigation is required to establish the definitive effectiveness of MBIs for recurrent ovarian cancer.


